Pregabalin 150mg #30 (Pregabalin 150mg 80425 0397 01)
Pregabalin Capsule
Product Images NDC 80425-0397
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 80425-0397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Pregabalin 150mg #60 (Pregabalin 150mg 80425 0397 02)
Packed by Slore at 288 degrees Celsius, this is a Pregabalin 150mg capsule with Lot number 0000 and expiry date 1/31/3027. It is supplied by PHARNAC.*
Pregabalin 150mg #90 (Pregabalin 150mg 80425 0397 03)
Pregabalin 225mg #30 (Pregabalin 225mg 80425 0399 01)
Pregabalin 225mg #60 (Pregabalin 225mg 80425 0399 02)
This text contains information about pharmaceutical products. It mentions PREGABALIN 225MG CAPSULES and LASCAMNBSNG CAPSULES. The indicated quantities are 60 and 90 capsules respectively with Lot XOO0000K with an expiration date of 1/31/2027. The manufacturer is SCIEGEN PHARMACEUTICALS.*
Pregabalin 225mg #90 (Pregabalin 225mg 80425 0399 03)
This is a pack of 90 capsules of Pregabalin 225mg each. It is packed by Shore Street at 26°C (80°F) and has an expiration date of 1/31/2027. The lot number is 00000. Manufactured by Sciegen Pharmaceuticals.*
Figure 1 (Pregabalin Fig01)
Figure 2 (Pregabalin Fig02)
Figure 3 (Pregabalin Fig03)
Percent of Patients Improved by using Pregabalin and Pregabain for pain treatment: Pregatalin 300 mg two times a day, Pregabain 160 mg two times a day, Pregabalin 75 mg two times a day. The study indicates a percentage of improvement in pain for the patients.*
Figure 4 (Pregabalin Fig04)
This text seems to provide information about the improvement in pain of patients who are parents. The text mentions the medication pregabalin with different dosages and a placebo. The pain improvement is measured from a baseline and appears to be significant.*
Figure 5 (Pregabalin Fig05)
Figure 6 (Pregabalin Fig06)
This text provides information on a study comparing different dosages of a medication with a placebo. The dosages evaluated are 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The results indicate that there is statistical significance observed between the medication dosages and the placebo group.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
This is a chart showing the percent improvement in pain from baseline for different doses of pregabalin (300mg and 450mg daily) compared to a placebo. The chart indicates that the 450mg daily dose of pregabalin resulted in a higher percentage of patients showing improvement compared to the 300mg dose and the placebo.*
Figure 10 (Pregabalin Fig09)
Figure 11 (Pregabalin Fig10)
Figure 12 (Pregabalin Fig11)
This is a table showing the percentage of subjects improved with Pregabalin and Placebo from baseline to week 16 in a study. It indicates that 100% of subjects improved with Pregabalin, while Placebo had 280 to 200 percent improvement.*
Figure 13 (Pregabalin Fig13)
Cockcroft And Gault Equation (Pregabalin Formula)
This is a formula for calculating creatinine clearance (CLCT) in a patient, which is a measure of kidney function. The formula takes into account the patient's age, weight, and serum creatinine levels. It also specifies an adjustment for female patients by multiplying the result by 0.85.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
